Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambervin in Hospitalized COVID-19 Patients
NCT05656495Phase 3Completed
- Sponsor
- Promomed
- Start
- Feb 2022
- Primary completion
- Nov 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Ambervin in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Promomed. Primary endpoint: Prevalence of patients with category 0-1 as per categorical ordinal clinical improvement WHO scale. Started Feb 2022; status: completed.
02
Drugs
Ambervin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05656495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656495.